M: +61 416 820 423
T: +61 7 3233 8913
E: bwood@mccullough.com.au

Recognised for Capital Markets and Corporate M&A

Legal 500 Asia-Pacific

 

Ben has a broad range of experience in assisting clients with issues relating to corporations and securities law, with a particular focus on public and private capital raisings, mergers and acquisitions and restructures.

Ben has assisted clients across a range of sectors including financial services, life sciences, technology, food and agribusiness, health and resources including ASX listed and large unlisted public companies, small to large proprietary companies and owner managed businesses.

Ben is also an integral member of the McR Private team, supporting our family office and private clients.

His expertise includes assisting clients with capital raisings (both IPOs and secondary raisings – including placements, rights issues and share purchase plans), unregulated mergers and acquisitions, including due diligence and deal implementation, and corporate reconstructions, including via court approved schemes of arrangement. Additionally he advises on directors’ duties and general corporate governance issues.

Originally from the UK, Ben is also admitted as a lawyer in England and Wales.

Read Ben’s latest publications:

 Former Irexchange executives in the sights for alleged misleading prospectus

  Fundamentals: Private Equity in Australia (Part II)

  Fundamentals: Private Equity in Australia (Part I)

  Deal protection – an international comparison

Experience

IPOs

Over the Wire Holdings Limited, OtherLevels Holdings Limited, Anatara Lifesciences Limited, and Delta SBD Limited.

Corporate Travel Management

Advising on the $43.7 million acquisition of Chambers Travel (UK/Europe) and $8.9 million acquisition of Diplomat Travel (USA), coupled with a $45.5 million renounceable entitlement offer.

Secondary capital raisings

Viralytics Limited, Tissue Therapies Limited, Invion Limited, Centrepoint Alliance Limited, Imugene Limited and King Island Scheelite Limited.

Centrepoint Alliance Limited

Advising on an acquisition scheme of arrangement to acquire the minority holdings in two dealer group businesses.

Biolife Science Qld Ltd

Acting on back door listing into ASX listed Imugene Limited and Pathway Oncology Pty Ltd into ASX listed Virax Holdings Limited.

Viralytics Limited

Advising on the $502 million acquisition of Viralytics Limitedby Merck by scheme of arrangement.

River City Labs

Advising on the sale of River City Labs Group to Australian Computer Society (ACS).